2025
Liver Fibrosis and Cardiovascular Events
Nso N, Bookani K, Trimingham M, Orji R, Njei B, Balasubramanian S, Pursnani A. Liver Fibrosis and Cardiovascular Events. Southern Medical Journal 2025, 118: 19-25. PMID: 39753232, DOI: 10.14423/smj.0000000000001769.Peer-Reviewed Original ResearchConceptsLiver fibrosis scoresNonalcoholic fatty liver diseaseRisk of cardiovascular eventsNAFLD fibrosis scoreCardiovascular eventsAll-cause mortalityFibrosis scoreLiver fibrosisSystematic reviewFibrosis-4Noninvasive liver fibrosis scoresLiver diseaseCardiovascular mortalityHigh risk of cardiovascular eventsNonalcoholic fatty liver disease fibrosis scoreRelevant prospective studiesSeverity of liver fibrosisNational Institutes of Health toolCardiovascular diseaseHigher liver fibrosis scoresSpectrum of cardiovascular diseasesFibrosis-4 scoreSeverity of fibrosisCardiovascular event occurrenceChronic liver disease
2024
Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status
Re V, Newcomb C, Carbonari D, Mezochow A, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Torgersen J. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology And Drug Safety 2024, 33: e70069. PMID: 39662972, PMCID: PMC11634562, DOI: 10.1002/pds.70069.Peer-Reviewed Original ResearchConceptsProton pump inhibitor initiationHazard ratioVeterans Health AdministrationSevere acute liver injuryProton pump inhibitorsChronic liver diseaseAcute liver injuryRates of hospitalizationSafety of medicationsPPI initiativesHealth AdministrationLiver disease statusMedication exposurePharmacoepidemiological studiesMedicationConfoundingScoresReports of hepatotoxicityDisease statusHepatotoxic medicationsDrug exposurePump inhibitorsHepatotoxic drugsOutpatient initiationHepatic safetyThe burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades
Al Ta’ani O, Aleyadeh W, Al-Ajlouni Y, Alnimer L, Ismail A, Natour B, Njei B. The burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades. BMC Public Health 2024, 24: 2979. PMID: 39468483, PMCID: PMC11514855, DOI: 10.1186/s12889-024-20445-5.Peer-Reviewed Original ResearchConceptsAge-standardized incidence rateAge-standardized death ratesDisability-adjusted life yearsBurden of cirrhosisGlobal Burden of DiseaseDisability burdenDeath rateAge-standardized disability-adjusted life yearsPublic health effortsBurden of diseaseSignificant health challengesGender-specific interventionsLiver disease incidenceChronic liver diseaseIncident casesMENA regionHealth effortsCountry-specific trendsHealthcare systemGlobal burdenHealth challengesIncreasing burdenIncidence rateLife yearsEpidemiological trends
2023
Clinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention
Lim J, Njei B. Clinical and Histopathological Discoveries in Patients with Hepatic Injury and Cholangiopathy Who Have Died of COVID-19: Insights and Opportunities for Intervention. Hepatic Medicine Evidence And Research 2023, 15: 151-164. PMID: 37814605, PMCID: PMC10560482, DOI: 10.2147/hmer.s385133.Peer-Reviewed Original ResearchAcute liver injuryCOVID-19 patientsPre-existing chronic liver diseaseCOVID-19Chronic liver diseaseSARS-CoV-2Immune dysregulationSupportive careBiliary dysfunctionHepatic injuryLiver injuryVascular changesLiver diseaseClinical manifestationsSignificant complicationsLong-term effectsDiagnostic criteriaTherapeutic targetCholangiopathyDiagnostic advancementsPatientsGlobal healthCOVID-19 pandemicInjuryDiverse manifestations
2019
Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma
Guerra MT, Florentino RM, Franca A, Lima Filho AC, Dos Santos ML, Fonseca RC, Lemos FO, Fonseca MC, Kruglov E, Mennone A, Njei B, Gibson J, Guan F, Cheng YC, Ananthanarayanan M, Gu J, Jiang J, Zhao H, Lima CX, Vidigal PT, Oliveira AG, Nathanson MH, Leite MF. Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. Gut 2019, 68: 1676-1687. PMID: 31315892, PMCID: PMC7087395, DOI: 10.1136/gutjnl-2018-317811.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsApoptosisCalcium SignalingCarcinogenesisCarcinoma, HepatocellularCell ProliferationCells, CulturedDNA MethylationFemaleGene Expression Regulation, NeoplasticHepatocytesHumansInositol 1,4,5-Trisphosphate ReceptorsLiverLiver NeoplasmsLiver RegenerationMaleMice, KnockoutMiddle AgedSurvival AnalysisConceptsChronic liver diseaseITPR3 expressionLiver cancer cellsLiver diseaseMouse modelFinal common eventCancer cellsSpecimens of patientsIndependent patient cohortsControl liver specimensHuman HCC cellsType 3 InsP3 receptorHuman liver samplesIncreased expression levelCancer deathPatient cohortCommon molecular eventPoor survivalHepatocellular carcinomaLiver specimensNormal liverHCC cellsAbstractTextHCCType 3 isoform
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply